Radial Research Aktie - RAD

Radial Research Corp (RAD) Aktie

Professionelle Tools für Privatanleger.

Premium

Current Price

0,135

( - )

Gebot

0,095

Fragen

0,135

Volumen

0,00 Tagesbereich 0,00

0,005 52-Wochen-Bereich 0,195

Marktkapitalisierung

375,815k

Handelsende

0,135

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

$ 9.982

Ausgegebene Aktien

2.783.818

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-2

Gewinn pro Aktie (EPS)

-0,05

Erlöse (LTM)

Nettogewinn (LTM)

-132,36k

Radial Research Corp. operates as a technology company in Canada. The company develops online and download technologies and services, including software, websites, and smartphone applications. Its projects include Zoompages, an e-commerce sales funnel content management system; The Commuter, a trip ... Radial Research Corp. operates as a technology company in Canada. The company develops online and download technologies and services, including software, websites, and smartphone applications. Its projects include Zoompages, an e-commerce sales funnel content management system; The Commuter, a trip planning application; Good Inc, a mobile application for pet donations; Rental Platform, a rent platform website and mobile application; and Trill Bank, a banking system. Radial Research Corp. was incorporated in 2017 and is based in Vancouver, Canada. Mehr anzeigen

Sektor

Technology

Branche

Software & It Services

Website

radial-research.com

Hauptsitz

Vancouver, Canada

Gegründet

2026

Radial Research Corp is listed in the Technology sector of the Canadian Securities Exchange with ticker RAD. The last closing price for Radial Research was $0,14. Over the last year, Radial Research shares have traded in a share price range of $ 0,005 to $ 0,195.

Radial Research currently has 2.783.818 shares in issue. The market capitalisation of Radial Research is $375.815,43 . Radial Research has a price to earnings ratio (PE ratio) of -2.00.

Radiopharm Theranostics Reports Business Update

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain...

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort ...

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary...

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or...

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in...

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission...

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.005	-3.57142857143	0.14	0.14	0.095	320	0.1228125	CS
4	0.045	50	0.09	0.155	0.09	733	0.13463281	CS
12	0.035	35	0.1	0.195	0.075	4520	0.11296597	CS
26	0.125	1250	0.01	0.195	0.005	10709	0.02996273	CS
52	0.125	1250	0.01	0.195	0.005	17396	0.01332994	CS
156	0.125	1250	0.01	0.195	0.005	7073	0.01338825	CS
260	0.055	68.75	0.08	0.195	0.005	5889	0.0170458	CS

RAD - Frequently Asked Questions (FAQ)

What is the current Radial Research Corp share price?

The current share price of Radial Research Corp is $ 0,135

How many Radial Research Corp shares are in issue?

Radial Research Corp has 2.783.818 shares in issue

What is the market cap of Radial Research Corp?

The market capitalisation of Radial Research Corp is CAD 375,82k

What is the 1 year trading range for Radial Research Corp share price?

Radial Research Corp has traded in the range of $ 0,005 to $ 0,195 during the past year

What is the PE ratio of Radial Research Corp?

The price to earnings ratio of Radial Research Corp is -2

What is the registered address of Radial Research Corp?

The registered address for Radial Research Corp is 890 West Pender Street, Vancouver, British Columbia, V6C 1J9

What is the Radial Research Corp website address?

The website address for Radial Research Corp is radial-research.com

Which industry sector does Radial Research Corp operate in?

Radial Research Corp operates in the Software & IT Services sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Radial Research Corp (RAD)

Radial Research Corp (RAD) Aktie

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Radial Research Corp

RAD Neueste Nachrichten

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

RAD Increases Ownership in Radiopharm Ventures to 87.5%

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

RAD - Frequently Asked Questions (FAQ)

RAD Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen